We are live on ! Find out more
DNA icon

Ginkgo Bioworks

6.99 USD
-0.02
0.29%
At close Updated Sep 15, 4:00 PM EDT
Pre-market
After hours
7.00
+0.01
0.14%
1 day
-0.29%
5 days
2.34%
1 month
1.01%
3 months
-15.07%
6 months
3.56%
Year to date
-19.66%
1 year
-31.94%
5 years
-98.57%
10 years
-98.57%
 

About: Ginkgo Bioworks Holdings Inc is the platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. The Company reorganized its operations into two operating and reportable segments: Cell Engineering engaged in providing biological R&D services for customers across a range of industries and Biosecurity that provides services to government and commercial customers to identify, monitor, prevent, mitigate, and ultimately protect humanity from biological threats. The maximum of revenue is from Cell Engineering Segment.

Employees: 485

News

Positive
Neutral
Negative
Sentiment 3-Months
Positive 0%
Neutral 100%
Negative 0%
Neutral
Business Wire
5 days ago
Ginkgo Bioworks Joins ARPA-H GIVE Program to Build Autonomous Manufacturing System for Individualized RNA Medicines
BOSTON--(BUSINESS WIRE)--Ginkgo Bioworks (NYSE: DNA) today announced that it has been awarded a subcontract for up to $17.5M under the Advanced Research Projects Agency for Health's (ARPA-H) Genetic Medicines and Individualized Manufacturing for Everyone (GIVE) program. Ginkgo will serve as a subcontractor to prime contractor Waterfall Scientific, Inc. on ESCALATOR (Engineering a Small-scale, Continuous-flow manufacturing Apparatus to Launch A Transformational Overhaul for RNA medicines), a mul.
Ginkgo Bioworks Joins ARPA-H GIVE Program to Build Autonomous Manufacturing System for Individualized RNA Medicines
Neutral
MarketBeat
1 month ago
Ginkgo Bioworks Q2 Earnings Call Highlights
Ginkgo Bioworks NYSE: DNA reported second-quarter 2026 revenue of $20 million, down 48% from the year-earlier period, as the company continued to shift its focus toward autonomous laboratory systems, contract research services and related software.
Ginkgo Bioworks Q2 Earnings Call Highlights
Neutral
Seeking Alpha
1 month ago
Ginkgo Bioworks Holdings, Inc. (DNA) Q2 2026 Earnings Call Transcript
Ginkgo Bioworks Holdings, Inc. (DNA) Q2 2026 Earnings Call Transcript
Ginkgo Bioworks Holdings, Inc. (DNA) Q2 2026 Earnings Call Transcript
Neutral
PRNewsWire
3 months ago
Ginkgo Datapoints, Tangible Scientific, and Inductive Bio Launch ADME-One™: a High-Throughput ADME Platform That Brings Pharmacokinetic Projection Earlier in Drug Discovery
New co-developed product delivers a complete Tier 1 ADME panel coupled with best-in-class AI-driven human pharmacokinetic (PK) projection and integrated compound management —enabling scientists to make lead-optimization-quality decisions starting in hit identification BOSTON, May 26, 2026 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA) today announced that its Datapoints offering is launching ADME-One™ , a fully integrated ADME platform for drug discovery teams co-developed with Tangible Scientific  and Inductive Bio . ADME-One delivers a high-throughput Tier 1 ADME (absorption, distribution, metabolism, and excretion) panel paired with best-in-class AI-powered human pharmacokinetic (PK) projection and fully integrated compound management.
Ginkgo Datapoints, Tangible Scientific, and Inductive Bio Launch ADME-One™: a High-Throughput ADME Platform That Brings Pharmacokinetic Projection Earlier in Drug Discovery
Negative
Seeking Alpha
4 months ago
Ginkgo Bioworks: Another Lost Year
Ginkgo Bioworks (DNA) reported Q1 revenues of $19.5M, down nearly 50% year-over-year and badly missing street estimates even after Biosecurity adjustments. Management is pivoting to autonomous labs but refuses to provide revenue guidance, causing analyst estimates to fall further. DNA continues to burn significant cash, with Q1 cash burn at $49M and 2026 guidance of $125M–$150M, leaving $373M in cash and no debt but weakening flexibility.
Ginkgo Bioworks: Another Lost Year
Negative
MarketBeat
4 months ago
Ginkgo Bioworks Q1 Earnings Call Highlights
Ginkgo Bioworks NYSE: DNA said it is sharpening its 2026 focus on autonomous laboratories after completing the divestiture of its biosecurity business and reporting lower year-over-year cash burn in the first quarter.
Ginkgo Bioworks Q1 Earnings Call Highlights
Neutral
PRNewsWire
4 months ago
Ginkgo Bioworks Reports First Quarter 2026 Financial Results, Completes Divestiture of Biosecurity and Continues to Scale Autonomous Lab
Ginkgo provides an update on its first quarter financial results following the divestiture of its Biosecurity business BOSTON, May 7, 2026 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE: DNA, "Ginkgo") today announced its results for the first quarter of 2026 that ended March 31, 2026. The update, including a webcast slide presentation with additional details on the first quarter, as well as supplemental financial information, will be available at investors.ginkgobioworks.com.
Ginkgo Bioworks Reports First Quarter 2026 Financial Results, Completes Divestiture of Biosecurity and Continues to Scale Autonomous Lab
Neutral
PRNewsWire
4 months ago
Ginkgo Bioworks Announces Date of First Quarter 2026 Results Presentation
Presentation and Q&A session scheduled for post-market on Thursday, May 7, 2026 BOSTON, April 30, 2026 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE: DNA, "Ginkgo") today announced that it plans to host a presentation and Q&A session reviewing business performance for the first quarter ended March 31, 2026, on Thursday, May 7, 2026, beginning at 4:30 p.m. ET. The presentation details and webcast link will be available on Ginkgo's investor relations website at https://investors.ginkgobioworks.com, and a replay will be made available.
Ginkgo Bioworks Announces Date of First Quarter 2026 Results Presentation
Neutral
Seeking Alpha
6 months ago
Ginkgo Bioworks Makes Major Pivot
Ginkgo Bioworks reported Q4 revenues of $33 million, down 24% year-over-year, and missing estimates by over $4 million. Cell Engineering, expected to drive growth, delivered just $125 million in 2025 revenue, far below the original $1.1 billion SPAC projection. Management is pivoting by selling the Biosecurity segment, retaining only a minority stake in the new private entity.
Ginkgo Bioworks Makes Major Pivot
Neutral
PRNewsWire
6 months ago
Ginkgo Bioworks Launches Ginkgo Cloud Lab, Powered by Autonomous Lab Infrastructure
BOSTON, March 2, 2026 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA) today announced the official launch of Ginkgo Cloud Lab. This new interface allows researchers to transition their benchwork to Ginkgo's autonomous lab infrastructure directly through a web browser.
Ginkgo Bioworks Launches Ginkgo Cloud Lab, Powered by Autonomous Lab Infrastructure
Price charts implemented using Lightweight Charts™